Lead Product(s) : Danuglipron
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Pfizer Advances Once-Daily Oral GLP-1 Agonist Danuglipron Development
Details : PF-06882961 (danuglipron) is an oral GLP-1R agonist smalll molecule candidate, which is being evaluated for the treatment of adults with obesity and without type 2 diabetes.
Brand Name : PF-06882961
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 11, 2024
Lead Product(s) : Danuglipron
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Danuglipron
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PF-06882961 (danuglipron) is an oral GLP-1R agonist smalll molecule candidate, which is being evaluated for the treatment of adults with obesity and without type 2 diabetes.
Brand Name : PF-06882961
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 01, 2023
Lead Product(s) : Danuglipron
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?